presents
EXPERT SPEAKERS
Prof. Tunde Peto
Professor of Clinical Ophthalmology,
Queen’s University Belfast
Global authority in retinal clinical trials and
public health ophthalmology; instrumental in
diabetic retinopathy screening programs across
multiple continents.
Prof. Chris McCabe
Co-Founder & CEO, Birota Health
Economics Group
Expert in health economics and policy translation, bringing decades of insight into healthcare decision-making and value demonstration.
Prof. Alan Stitt, FARVO
Dean of Innovation and Impact, Queen’s
University Belfast | Co-Founder & Chief
Scientific Advisor, MediNect Ophtho
Renowned retinal biologist and research leader,
with a track record in translational
ophthalmology and academic-industry
partnerships.
Dr James Bojdo
Founder & Programme Director, RetInnovate
Co-Founder & CEO, MediNect Ophtho
Translational science strategist, dedicated to
fostering innovation and commercialisation in
retinal therapeutics.
Paul Ryb
Managing Director, Head of Ophthalmology,
Outcome Capital
30 years' experience in investment banking,
15 years dedicated to ophthalmology
Jaspreet Grewal, MBA
Founder, Venn Consulting & Axial Bridge |
Clinician Researcher | Partner, Cerulean Health
Specialist in health innovation ecosystems and
biotech translation. Recognised for connecting
academic innovation to commercial pathways.
Dr Tim Belcher
Partner, eIP International Law Firm
Specialist in intellectual property law for life
sciences and medtech, advising startups
through to IPO-ready ventures.
Dr Stephen Ligget
Director, Future Medicines Institute
Visionary in precision medicine and novel
therapeutic platform development, with a focus
on future-oriented pharmaceutical innovation.
Dr Tine Van Bergen
Founder & Preclinical Regulatory Consultant,
OcuRes Consult | Scientific Advisor, MediNect Ophtho
Expert in nonclinical ophthalmology and regulatory
science, advising companies on IND-enabling studies
and preclinical strategy.
Registration
-
Ticket to 2-day event
-
13th November 2025 - 8.30am - 5.30pm
-
14th November 2025 - 8.30am - 5.30pm
-
-
Refreshments, coffee and lunch on both days
-
Networking dinner and drinks with clinicians attending EVICR.net
-
Invited to pitch event - winner receives £25k research grant (application form required; Ts & Cs apply)
EarlyBird - before 30th September
£449
(+VAT & Admin Fee)
£749
(+VAT & Admin Fee)
£1199
(+VAT & Admin Fee)
After 30th September
£649
(+VAT & Admin Fee)
£1099
(+VAT & Admin Fee)
£1499
(+VAT & Admin Fee)
Thanks to our sponsors!
Main Sponsor
Your Partner in Retinal Research Innovation
We’re a UK-based preclinical CRO driving breakthroughs in retinal disease. From wet & dry AMD, GA, DME, RP, Stargardt, Wolfram Syndrome, DR, and retinopathy of prematurity to glaucoma — our bespoke rodent and ex vivo models deliver precision insights. Our toolbox includes advanced inflammatory profiling (20 markers/eye), IHC, flatmount staining, AI-driven analysis, ELISA, WB, RNA-seq, rabbit PKs, and more — all designed to accelerate your path from discovery to clinic.
Supported by
.png)
Connecting the dots in life science innovation from concept through to market acceptance
Join us in facilitating the flow of innovations to market
FlowCo is a dynamic hub uniting investors, thought leaders, and start-ups in the ophthalmology biotech space. We want to play our part in improving the development of therapeutics of the future, bringing revolutionary treatments to patients by educating the brains behind the innovations to give better understanding of the drug development process all the way to the market. Specialising in fostering collaboration in the different therapeutic areas, we curate specialist intimate events that bring together innovators, investors and enablers. Explore our inaugural Retinal Innovation Bootcamp event, Retinnovate 2025, to ensure you stand out from competitors to Investors by ensuring you iterate your drug development pathway.
Upcoming initiatives
Retinnovate 2025 Bootcamp: Belfast
A premier focused meeting preparing retinal therapeutic market development program.
Main Sponsor
A UK-based preclinical collaborative research partner embedded with academic expertise from leading KOLs in the field of retinal disease.
Supported by
.png)
